Fig. 5. VIP152 improves survival in the Eµ-MTCP1 CLL model.

20 C57BL/6 J mice were engrafted via tail vein with 10⁶ splenocytes from leukemic Eµ-MTCP1 mice. A Schematic cartoon of in vivo adoptive transfer study. B–D Measurement of peripheral disease as characterized by CD45⁺/CD5⁺/CD19⁺ % in peripheral blood (B), weight monitoring (C), and survival (D) of mice following enrollment upon either VIP152 (blue) or vehicle treatment (red). 10 mice were enrolled into each treatment arm. (*,** = p < 0.01 and p < 0.005 respectively). Error bars indicate mean of surviving mice ± SEM.